Starts & Stops: Abbott, Boston Scientific Head List Of Early 2018 Trial Announcements
Starts & Stops is a regular feature in Medtech Insight highlighting noteworthy clinical trial announcements, initiations, completions, and suspensions tracked by Meddevicetracker. This edition covers the start of 2018, which includes important trial announcements from Abbott, Boston Scientific, Medtronic, Edwards and many more. The Stops & Starts feature will be switching to a weekly schedule as of March 5 to offer more timely updates on medical device trials.
You may also be interested in...
The global vascular stents market is expected to reach $8.8bn by 2021, driven primarily by the growing prevalence of cardiovascular disease, the leading cause of death worldwide. Limitations of current stent products are fueling innovations by the three big heart players - Abbott, Boston Scientific and Medtronic - as well as startups to develop next-generation drug-eluting and bioresorbable stents that can reduce the risk of adverse event. This feature looks more closely at the competitive landscape of the overall vascular stent market focusing in particular on the changing dynamics of drug-eluting stents, which is the largest and second-fastest segment in this overall market, including its use for treating peripheral artery disease, along with physician surveys and perspectives.
Starts & Stops: Mercator Looking To Leap Into New Indications For Bullfrog Micro-Infusion Drug-Delivery
Starts & Stops is a regular feature highlighting Medtech Insight's monthly editors' picks of noteworthy medtech clinical trial announcements, initiations, completions, and suspensions. This month's edition, covering November, is led by a major milestone for Mercator Medsystems, developer of the Bullfrog micro-infusion catheter.
Many medtech companies reported their sales and earnings for all of 2016, along with projections for 2017, at the end of January or early February. Medtech Insight has examined their reports as well as the comments of the analysts who track these companies to highlight a few that had especially good years, some that had down years, and some lesser-known companies worth watching in the future.